Gilead Takes $300 Million Stake in Cancer Antibody Developer Tizona

Gilead Sciences said it is buying a 49.9 percent stake in Tizona Therapeutics, a company developing first-in-class cancer immunotherapies, for $300 million in a transaction expected to close in the third quarter of this year.
Source: Devices & Diagnostics Letter